Tumor necrosis factor receptor superfamily member 11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG1 Kappa

ABM10D2

Mouse

Purified
Protein G Chromatography

25 ug in 50 ul/100 ug in 200 ul PBS containing 0.05%?BSA and 0.05% sodium azide. Sodium azide is highly toxic.

Store the antibody at 4 degree C, stable for 6 months.
For long-term storage, store at -20 degree C.
Avoid repeated freeze and thaw cycles.

Small volumes of anti-OPG antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

OPG (Osteoprotegerin) belongs to the TNF receptor super-family and is implicated in bone remodeling and in the atherosclerotic process. This molecule acts as a decoy receptor for the RANKL (Receptor Activator of Nuclear Factor-KappaB Ligand), inhibiting binding of RANKL to its receptor, RANK. OPG acts as a soluble neutralizing receptor of TRAIL (TNF-Related Apoptosis-Inducing Ligand), an anti-inflammatory molecule with anti-atherosclerotic properties. Mostly implicated in bone remodeling, the RANK/RANKL/OPG axis is involved in immune and vascular system. OPG has been associated with increased risk of atherosclerotic disease in the general population. OPG has also been associated with increased pulse wave velocity, progression of arterial calcification and with mortality in both end-stage renal failure patients as well as the general population.

Antibodies; NF-kB Pathway

Flow Cytometry (FC/FACS), Western Blot (WB)

WB: 4-6 ug/ml
Flow Cytometry: 0.5-1 ug/10^6

Fig-1: Western blot analysis of OPG. Anti-OPG antibody (Clone: ABM10D2) was used at 4 ug/ml on Hela lysate.

Fig-2: Intracellular Flow analysis of OPG antibody on Ramos cells using 0.5 ug/ 10^6 cells of anti-OPG antibody (ABM10D2). Green represents isotype control; red represents anti-OPG antibody. Goat anti-mouse FITC conjugate was used as secondary antibody. (Cells were fixed with 4% paraformaldehyde for 10 min and washed with PBS by centrifuging at 1100 for 5 min followed by permeabilization for 20 min and washed again as mentioned above. Then cell were incubated with primary antibody for 45 min. and after washing the cells twice in PBS, incubated with conjugated secondary antibody for 30 min. Data acquisition was done after washing twice with PBS as mentioned above).

46,026 Da

TNF receptor superfamily member 11b

tumor necrosis factor receptor superfamily member 11B

Tumor necrosis factor receptor superfamily member 11B

OCIF; OPG??[Similar Products]

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal.

Protein type: Inhibitor; Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 8q24.12

Cellular Component: extracellular region; extracellular space; integral to plasma membrane; plasma membrane

Molecular Function: cytokine activity; receptor activity; tumor necrosis factor receptor activity

Biological Process: immune response; inflammatory response; positive regulation of MAPKKK cascade; regulation of apoptosis; regulation of cell proliferation; response to lipopolysaccharide; signal transduction; skeletal development; tumor necrosis factor-mediated signaling pathway

Disease: Paget Disease, Juvenile

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.